Platelet adhesion to vascular subendothelium is the initial step in both normal hemostasis and arterial thrombosis. The plasma protein von Willebrand Factor (VWF) plays an important role in platelet thrombus formation, because it binds strongly to the collagen in the subendothelium and to the platelet receptor GPIb. This bridge function is critical to stabilize the interaction between platelets and subendothelium under high shear and high flow conditions present in the arterial and microcirculation. The A1, A2, and A3 domains mediate key interactions for VWF. The A1 domain binds to GPIb, heparin, sulphatides and collagen Type VI. Conformational changes are thought to expose the VWF-A1 domain after the binding of other regions in VWF to collagen. The VWF-A2 domain contains a physiological cleavage site that is associated with the metalloprotease ADAMTS13 in plasma. The VWF-A3 domain contains the major collagen-binding site for fibrillar collagens. The importance of the A domains in VWF is underscored by the inherited bleeding disorder Type 2 von Willebrand disease (VWD), which corresponds to functional abnormalities in VWF. The mutated residues that cause the variants of Type 2A, 2B, and 2M VWD have been found in the VWF-A1 and VWF-A2 domains. The goal of this grant is to understand the molecular mechanism by which the VWF-collagen interaction induces the VWF-A1 to assume the active conformation that results in binding to platelet GPIb. In the first aim, we plan to describe the residues that make contact with collagen within the VWF-A3 domain. We will also test the hypothesis that the VWF-A1 and VWF-A3 domains have a direct interaction. In the second aim we will make recombinant VWF-A2, VWF-AIA2, and VWF-A2A3 proteins to analyze the role of the VWF-A2 domain in the VWF-binding to both GPIb and collagen. We will also study the molecular mechanism by which Type 2A mutations increase the sensitivity of the VWF-A2 domain for proteolysis.
The third aim will characterize the binding of the recombinant VWF-AIA2A3 protein to GPIb and collagen and the interaction with plasma metalloprotease. We will study the effects of interesting mutants identified in the two previous aims together with some Type 2B mutations on the affinity and regulation of the VWF-A1A2A3. For the last two specific aims, we plan to analyze the role of glycosylation on the GPIb and collagen binding and in plasma metalloprotease activity. The new information obtained from this work will establish the structural basis by which VWF multimers is activated and regulated. It may also contribute to the development of an effective assay to detect the activity of the metalloprotease in plasma. It will provide molecular guidance for the generation of reagents to treat arterial thrombosis.

National Institute of Health (NIH)
National Heart, Lung, and Blood Institute (NHLBI)
Research Project (R01)
Project #
Application #
Study Section
Hemostasis and Thrombosis Study Section (HT)
Program Officer
Ganguly, Pankaj
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Baylor College of Medicine
Internal Medicine/Medicine
Schools of Medicine
United States
Zip Code
Nguyen, Trung C; Gushiken, Francisca; Correa, Juliana I et al. (2015) A recombinant fragment of von Willebrand factor reduces fibrin-rich microthrombi formation in mice with endotoxemia. Thromb Res 135:1025-30
Ju, Lining; Chen, Yunfeng; Zhou, Fangyuan et al. (2015) Von Willebrand factor-A1 domain binds platelet glycoprotein Ib? in multiple states with distinctive force-dependent dissociation kinetics. Thromb Res 136:606-12
Ju, Lining; Dong, Jing-fei; Cruz, Miguel A et al. (2013) The N-terminal flanking region of the A1 domain regulates the force-dependent binding of von Willebrand factor to platelet glycoprotein Ib?. J Biol Chem 288:32289-301
Auton, Matthew; Sowa, Katie E; Behymer, Molly et al. (2012) N-terminal flanking region of A1 domain in von Willebrand factor stabilizes structure of A1A2A3 complex and modulates platelet activation under shear stress. J Biol Chem 287:14579-85
Auton, Matthew; Zhu, Cheng; Cruz, Miguel A (2010) The mechanism of VWF-mediated platelet GPIbalpha binding. Biophys J 99:1192-201
Wu, Tao; Lin, Jiangguo; Cruz, Miguel A et al. (2010) Force-induced cleavage of single VWFA1A2A3 tridomains by ADAMTS-13. Blood 115:370-8
Auton, Matthew; Sowa, Katie E; Smith, Scott M et al. (2010) Destabilization of the A1 domain in von Willebrand factor dissociates the A1A2A3 tri-domain and provokes spontaneous binding to glycoprotein Ibalpha and platelet activation under shear stress. J Biol Chem 285:22831-9
Auton, Matthew; Sedlak, Erik; Marek, Jozef et al. (2009) Changes in thermodynamic stability of von Willebrand factor differentially affect the force-dependent binding to platelet GPIbalpha. Biophys J 97:618-27
Yago, Tadayuki; Lou, Jizhong; Wu, Tao et al. (2008) Platelet glycoprotein Ibalpha forms catch bonds with human WT vWF but not with type 2B von Willebrand disease vWF. J Clin Invest 118:3195-207
Dong, Jing-fei; Cruz, Miguel A; Aboulfatova, Khatira et al. (2008) Magnesium maintains endothelial integrity, up-regulates proteolysis of ultra-large von Willebrand factor, and reduces platelet aggregation under flow conditions. Thromb Haemost 99:586-93

Showing the most recent 10 out of 15 publications